-
Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks' gestation: relation to fetal and maternal characteristics and pregnancy outcomes.
Poon LC, Musci T, Song K, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2013;33:215-23. pdf -
Maternal serum placental growth hormone at 11-13 weeks' gestation in pregnancies delivering small for gestational age neonates.
Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH.
J Matern Fetal Neonatal Med 2012;25:1796-9. -
Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks.
Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH.
Fetal Diagn Ther 2011;29:148-54. -
Fetal RHD genotype detection from circulating cell-free fetal DNA in maternal plasma in non-sensitized RhD negative women.
Bombard AT, Akolekar R, Farkas DH, Vanagtmael AL, Aquino F, Oeth P, Nicolaides KH.
Prenat Diagn 2011;31:802-8. -
Fetal RHD Genotyping in Maternal Plasma at 11-13 Weeks of Gestation.
Akolekar R, Finning K, Kuppusamy R, Daniels G, Nicolaides KH.
Fetal Diagn Ther 2011;29:301-6. -
Platelet changes and subsequent development of pre-eclampsia and fetal growth restriction in women with abnormal uterine artery Doppler screening.
Missfelder-Lobos H, Teran E, Lees C, Albaiges G, Nicolaides KH.
Ultrasound Obstet Gynecol 2002;19:443-8. -
Vasoactive mediator release by fetal endothelial cells in intrauterine growth restriction and preeclampsia.
Parra MC, Lees C, Mann GE, Pearson JD, Nicolaides KH.
Am J Obstet Gynecol 2001;184:497-502.